A St. Louis jury sided with Enfamil maker Mead Johnson, rejecting claims that its specialized preterm infant formula caused a baby girl to develop necrotizing enterocolitis (NEC). The verdict is the latest in nearly 1,000 similar lawsuits filed against Mead Johnson and Abbott Laboratories. The companies maintain their products do not cause NEC, though trial outcomes have been mixed.
A Missouri jury has ruled in favor of Mead Johnson — the Reckitt unit behind Enfamil — dismissing claims that its specialized hospital-grade formula for premature infants caused a baby girl to develop necrotizing enterocolitis (NEC), a life-threatening bowel disease. The lawsuit was brought by Illinois mother Cadence Collins, who alleged her daughter suffered lifelong injuries after consuming the product.
This verdict is part of a much larger legal battle. Nearly 1,000 similar lawsuits have been filed against both Mead Johnson and Abbott Laboratories (maker of Similac), with over 700 cases consolidated in Illinois federal court and others pending in state courts. The companies argue that while breast milk is known to protect against NEC, their formulas do not cause it — a position they say clinicians have long been aware of.
Key Takeaways:
Why it matters: These cases carry major implications for the availability of specialized nutrition products used in NICUs nationwide. A wave of adverse verdicts could jeopardize access to hospital-grade preterm formulas for the most vulnerable newborns.
